Dosing protocol · Healing & Recovery
ARA-290 (Cibinetide) dosing & administration
A peptide that awakens your body's natural repair system to heal damaged nerves and reduce pain
Suggested dose
1 – 8 mg
137 peptides · 10 goals
Goals
Cognitive
Cosmetic
Growth Hormone
Healing & Recovery
Hormone Support
Immune
Metabolic
Mitochondrial
Sexual Health
Sleep & Recovery
Dosing protocol · Healing & Recovery
A peptide that awakens your body's natural repair system to heal damaged nerves and reduce pain
Suggested dose
1 – 8 mg
Dosing
Subcutaneous
Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
3 documented dose levels — separate regimens, not a titration schedule
1 mg
Lowest dose tested in the phase 2 sarcoidosis nerve study. A good starting point while watching how the body responds .
4 mg
The 4 mg dose gave the strongest nerve-fiber regrowth and pain relief in the trial — better than the higher 8 mg dose .
8 mg
Highest daily dose studied in the sarcoidosis trial. It was safe but did not beat 4 mg for nerve outcomes .
Intravenous
Intravenous: Delivered straight into a vein through a drip (IV), done by a clinician.
Bioavailability Complete (about 100%) — delivered straight into the bloodstream.
Timing
Best time to take
Administer ARA-290 (Cibinetide) at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.
With food?
ARA-290 (Cibinetide) injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.
If stacking
ARA-290 (Cibinetide) should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting your dose
Increase if
Decrease if
Signs of right dose
Administration
Reconstitution
What you need
Injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Storage
Before reconstitution
Store ARA-290 (Cibinetide) in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
After reconstitution
Once reconstituted, ARA-290 (Cibinetide) should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Signs of degradation — discard the vial
Sample daily schedule
As prescribed (once daily)
As prescribed by your healthcare provider injection
Site: Subcutaneous injection—rotate sites if applicable
Maintain a consistent schedule for optimal results with ARA-290 (Cibinetide). Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.
Safety
Side effects
Commonly reported: Injection Site Reactions, Headache, Dizziness
Less common: Elevated Blood Pressure, Fatigue
Serious side effects
Stop and seek help if
ARA-290 (Cibinetide) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Flagged pairings
Published research
ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes
ARA-290 treatment resulted in significant improvement of neuropathic pain in diabetic patients along with increased corneal nerve fibers. The peptide showed disease-modifying properties with long-lasting beneficial effects on both pain-related and non-pain-related symptoms.
Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain
Cibinetide at 4 mg daily significantly increased corneal nerve fiber area by 697 μm², along with increased regenerating intraepidermal fibers. Pain improved significantly in all groups, with changes in nerve fiber abundance correlating with improvements in walking distance and pain severity.
Corneal nerve fiber size adds utility to the diagnosis and assessment of therapeutic response in patients with small fiber neuropathy
Corneal nerve fiber area measurements proved useful for tracking therapeutic response to ARA-290 treatment in neuropathy. The metric showed quantifiable changes in nerve morphology and provided superior sensitivity to identify nerve repair compared to skin biopsy.
Erythropoietin-derived nonerythropoietic peptide ameliorates experimental autoimmune neuritis by inflammation suppression and tissue protection
ARA 290 greatly improved recovery from autoimmune nerve inflammation by promoting nerve regeneration and remyelination while suppressing inflammation. The treatment increased protective regulatory T cells and reduced pro-inflammatory immune responses.
ARA 290 for treatment of small fiber neuropathy in sarcoidosis
ARA 290 treatment was associated with significant improvements in neuropathic pain, increased corneal nerve fibers, improved sensory thresholds, and better quality of life in sarcoidosis patients. The excellent safety profile combined with disease-modifying properties makes it promising for treating this orphan disease.
Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study
Intravenous ARA 290 at 2 mg three times weekly for 4 weeks improved small fiber neuropathy symptoms versus placebo in sarcoidosis patients.
Head to head
The complete ARA-290 (Cibinetide) research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.